Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors by Manganaro, Roberto et al.
Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C 
inhibitors. 
 
Roberto Manganaro1*, Birgit Zonsics1*, Lisa Bauer2*, Moira Lorenzo Lopez1, Tim Donselaar2, 
Marleen Zwaagstra2, Fabiana Saporito1, Salvatore Ferla1, Jeroen R.P.M. Strating2, Bruno 
Coutard3, Daniel L. Hurdiss2, Frank J.M. van Kuppeveld2, Andrea Brancale1 
 
1 School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, 
Cardiff CF10 3NB, UK; 
2 Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary 
Medicine, Utrecht University, 3584CL Utrecht, the Netherlands; 
3 Unité des Virus Emergents, (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU 




Short Communications  
Word Count: 1753 
  
Abstract: 
Enteroviruses (EV) are a group of positive-strand RNA (+RNA) viruses that include many 
important human pathogens (e.g. poliovirus, coxsackievirus, echovirus, numbered 
enteroviruses and rhinoviruses). Fluoxetine was identified in drug repurposing screens as 
potent inhibitor of enterovirus B and enterovirus D replication. In this paper we are reporting 
the synthesis and the antiviral effect of a series of fluoxetine analogues. The results obtained 
offer a preliminary insight into the structure-activity relationship of its chemical scaffold and 
confirm the importance of the chiral configuration. We identified a racemic fluoxetine analogue, 
2b, which showed a similar antiviral activity compared to (S)-fluoxetine. Investigating the 
stereochemistry of 2b revealed that the S-enantiomer exerts potent antiviral activity and 
increased the antiviral spectrum compared to the racemic mixture of 2b. In line with the 
observed antiviral effect, the S-enantiomer displayed a dose-dependent shift in the melting 
temperature in thermal shift assay, indicative for direct binding to the recombinant 2C protein. 
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Enteroviruses (EV) form the largest genus in the Picornaviridae family of positive-strand RNA 
(+RNA) viruses and include many important human pathogens (e.g. poliovirus, 
coxsackievirus, echovirus, numbered enteroviruses and rhinoviruses). Infections with EV 
cause a wide variety of clinical manifestations ranging from mild diseases like hand-foot-and-
mouth disease, conjunctivitis to severe conditions like aseptic meningitis, severe neonatal 
sepsis like diseases and acute flaccid paralysis and myelitis. Rhinoviruses (RV) cause the 
common cold and can trigger exacerbation of asthma and chronic obstructive pulmonary 
disease (COPD). (1) These diseases are mostly self-limiting but can give rise to life-
threatening respiratory and/or neurological complications especially in infants, young children 
and immunocompromised individuals. The increasing outbreaks of EV-D68 and several other 
emerging enteroviruses (e.g. EV-A71 and CV-A16) with severe neurological complications 
worldwide exemplify the public health threat emerging from EVs. (2–4) Despite their huge 
socioeconomical and medical burden, vaccines only exist against poliovirus and EV-A71, for 
which vaccines were recently approved in China. (5) Currently, no antiviral therapy to combat 
EV infections is approved and treatment is limited to supportive care. 
Fluoxetine (Prozac®), a selective serotonin reuptake inhibitor (SSRI) licensed for the 
treatment of major depression and anxiety disorders, was identified in drug repurposing 
screens as potent inhibitor of enterovirus B and enterovirus D replication. (6,7) Mode-of-action 
studies revealed that only the S-enantiomer of fluoxetine inhibits viral replication by directly 
binding to the non-structural protein 2C. (8) The ATPase dependent RNA helicase 2C is a highly 
conserved non-structural protein among EVs and involved in pleiotropic functions during the 
viral life cycle (uncoating, RNA replication, encapsidation, membrane rearrangement). (9–17) 
Fluoxetine was shown to inhibit EV-B replication in mice and additionally has already been 
successfully used to treat an immunocompromised child with life-threatening chronic 
enterovirus encephalitis. (18,19) Together this indicates that fluoxetine offers a potential option 
as antiviral therapy for clinical use. Here, we report an initial investigation of a series of 
fluoxetine analogues, in which we introduce some basic changes in the original scaffold, to 
gain an early insight into the structure-activity relationships of fluoxetine. 
We previously reported a profiling of several fluoxetine fragments and described that the 
fragment N-Methyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine showed modest antiviral 
activity against coxsackievirus B3 (CVB3). (20) This result indicated that the structural features 
of the trifluoro-phenoxy moiety and the amino moiety are essential for the antiviral activity 
whereas the 3-phenyl moiety seems dispensable. The para-trifluoro-phenoxy moiety is crucial 
for the SSRI activity because changes of the substituent lower the affinity towards the 
serotonin transporter (SERT) (21). Hence, fluoxetine analogues with modifications on the CF3-
substituent positions on the phenoxy ring were synthesized. Rather than in para position, the 
CF3 group was placed in ortho or in meta position on compounds 1a and 1b, respectively. In 
compounds 1c and 1d, an additional substituent in ortho position was introduced to the parent 
compound (22).  
The second moiety of interest was the methylamine group. The well-characterised pan-
enterovirus inhibitor guanidine hydrochloride (GuaHCl) has been shown to target 2C (23). We 
designed fluoxetine analogues substituting the methylamine group with GuaHCl. Compounds 
5a and 5b differ in the length of the linker chain accounting for the additional atom in GuaHCl 
compared to the methylamine. Further, in compound 3 the N-methyl group was replaced by 
an acetyl group, to explore the need of a basic nitrogen in that position. 
CVB3 causes an observable cytopathic effect (CPE) apparent as rounding, detachment and 
eventually dying of cells. The newly synthesized compounds where tested in a multicycle CPE-
reduction assay to elucidate whether they were capable of inhibiting virus replication and 
thereby preventing the formation of CPE similar to fluoxetine. Therefore, subconfluent 
HelaR19 cells were treated with a concentration range of compounds and the cells were 
immediately infected with CVB3 at MOI 0.001 resulting in full CPE in the infected control 
without compound treatment within 3 days. In parallel, cytotoxicity was determined using a 
colorimetric method using the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) salt (MTS). It should be noted at this point that all compounds 
where synthesized as racemic mixture and therefore both the racemic mixture as well as the 
enantiomers of fluoxetine were used as positive controls. Changing the CF3 substituent from 
para to ortho or meta position or introducing a second substituent on the ring abolished the 
antiviral activity of compounds 1a-1d (Table 1). On the contrary, compounds 2a, 2b and 4a, 
which contained changes on the amino moiety, retained antiviral activity. Changing the N-
methyl group to the acetamide group resulted in the inactive compound 3 (Table1).  
Like fluoxetine, compound 2b was synthesized and tested as a racemic mixture. It proves to 
be as potent in inhibiting CVB3 replication as (S)-fluoxetine and 10-fold more potent than 
racemic fluoxetine. To exclude a cell-type specific effect of the antiviral efficacy and to evaluate 
the cytotoxicity of compounds 2a and 2b, multicycle assays using different cell lines was 
performed. Subconfluent HEK239T cells and HAP1 cells were treated with serial dilution of 
the compounds 2a and 2b and cytotoxicity as well as antiviral activity against CVB3 were 
evaluated in parallel. Compound 2a and compound 2b show the same range of antiviral 
activity against CVB3 in all cell lines. Importantly, both compounds are 2- to 3-fold less 
cytotoxic than racemic or (S)-fluoxetine in all three cell lines tested (Table 2). For unknown 
reasons, compounds 2a and 2b did not show antiviral activity in the monkey cell lines BGM 
and Vero (data not shown). Taken together, changes in the trifluoro phenoxy part of the 
molecule resulted in loss of antiviral activity. Modifications on the amine part were tolerated 
and increased the antiviral activity and the selectivity index (SI) of the compounds slightly.  
To investigate the broad-spectrum anti-enteroviral activity of the compounds 2a and 2b, Hela 
R19 cells were infected with representative virus serotypes of different enteroviruses species 
in both a multicycle CPE reduction assay (MOI 0.001 or 0.01, depending on virus, see 
Supplementary Information) and in a single cycle assay (MOI 1) in which virus reproduction 
was evaluated after 8 h or 10 h of infection (depending on virus, see Supplementary 
Information). Both, 2a and 2b inhibited CVB3 and EV-D68, but not EV-A71 or representatives 
of the EV-C species (poliovirus and CV-A24) (Table 3 and Figure 1). Compound 2b showed 
a slightly higher potency towards CVB3 and EV-D68 compared to compound 2a. Unlike 
racemic fluoxetine, 2b also inhibited HRV-14 replication. Notably, 2b inhibited HRV-14 even 
more potently than (S)-fluoxetine. However, unlike (S)-fluoxetine, 2b did not inhibit HRV-2 
(Table 3 and Figure 1).  
Over the last decades several structurally disparate 2C inhibitors were identified but the mode 
of action is poorly understood. (24) We previously reported the putative binding area of (S)-
fluoxetine in a homology model of CVB3 2C, which was based on the published crystal 
structure of EV-A71 2C, and provided experimental support for that model through mutational 
analysis of potential interacting residues. (20,25) We demonstrated that the triple mutations 
A224V-I227V-A229V, which gives cross resistance towards most of the 2C inhibitors, (16) as 
well as the single mutations I227V, C179F and F190L conferred resistance towards (S)-
fluoxetine. (20) To explore if the newly synthesized compounds have a similar resistance 
profile, and thus potentially occupy the same binding site, we infected Hela R19 cells with 
viruses carrying mutations which confer resistance to (S)-fluoxetine. Viruses harbouring the 
2C triple mutations A224V-I227V-A229V or the single mutations I227V, C179F or F190L were 
tested for cross-resistance towards the novel analogues 2a and 2b. HelaR19 cells were 
infected with mutant viruses at an MOI of 1 and virus titers were determined by endpoint 
titration at 8 hours post infection. The triple mutant A224V-I227V-A229V conferred a high level 
of resistance towards both compound 2a and 2b as it does to (S)-fluoxetine. Remarkably, the 
single mutation I227V showed resistance towards (S)-fluoxetine but not against the new 
analogues 2a or 2b. The residue C179F conferred resistance towards (S)-fluoxetine and 2b, 
but not against 2a. Notably, the mutation F190L did not confer resistance to either 2a or 2b. 
Summarized, the overall resistance profile for the new compounds is very similar to (S)-
fluoxetine but not identical. This suggests that the compounds likely occupy the same binding 
pocket as (S)-fluoxetine, but the exact binding mode could be slightly different. Unfortunately, 
the lack of an experimental structure of the fluoxetine/2C complex does not yet allow us to 
generate an accurate binding model for the newly reported compounds. 
Given the improved antiviral activity of the racemic mixture of 2b, we dissected the role of the 
two 2b-enantiomers. The antiviral activity of the enantiomers was evaluated in a multicycle 
assay. The S-enantiomer of 2b showed a ~3-4 fold increased antiviral activity against CVB3, 
EV-D68 and HRV-14 compared to the racemic 2b and (S)-fluoxetine (Figure 3A). Additionally, 
the S-enantiomer but not the racemic mixture of 2b also inhibited HRV-2 (Figure 3A). 
Remarkably, the R-enantiomer showed subtle antiviral activity against CVB3 and EV-D68 
(Figure 3A). Both enantiomers did not inhibit EV-A71 or the representative members of the 
EV-C species (PV-1 and CV-A24, data not shown). Additionally, we investigated the binding 
of the two enantiomers to a recombinant fragment of CVB3 2C (116) using a thermal shift 
assay. As reported previously, (S)-fluoxetine shifted the melting temperature of 2C in a dose-
dependent manner. Consistent with the antiviral activity, the 2b S-enantiomer caused a dose-
dependent shift in the melting temperature of 2C, indicative of direct binding. Unlike (R)-
fluoxetine, a thermal shift was also observed for the 2b R-enantiomer of 2b at higher 
concentrations. This suggests that the R-enantiomer of 2b exerts indeed subtle antiviral 
activity.  
In conclusion, our study established that the introduced changes on the para-trifluoro-phenoxy 
moiety of fluoxetine resulted in the loss of antiviral activity. Although it may not be possible to 
fully uncouple the SSRI activity from the antiviral activity, it appears that modifications on the 
amine moiety can increase the antiviral activity and reduce cytotoxicity. Additionally, we 
confirmed the importance of the chiral configuration in maintaining the antiviral activity. Similar 
to fluoxetine, the antiviral activity of the 2b S-enantiomer was higher compared to the R-
enantiomer or the racemic mixture of 2b. Interestingly, unlike (R)-fluoxetine, the 2b R-
enantiomer gained subtle antiviral activity against CV-B3 and EV-D68. In line with the antiviral 
activity, the S-enantiomer as well as high concentrations of R-enantiomer caused a dose-
dependent thermal shift of 2C, suggestive of a direct interaction. Known resistance mutations 
confer cross-resistance to the analogues 2a and 2b and our data indicate that the novel 
compounds interact with 2C in a similar manner as (S)-fluoxetine. However, the observed 
variations in the resistance profile of the two drugs point to subtle differences in the interaction 
with the 2C protein.  
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Table 1: Sensitivity of CVB3 to Fluoxetine Analogues 
Shown are EC50 and CC50 values in µM. Data represents mean values ± standard deviation 
calculated from three independent experiments and each experiment was performed in 
biological triplicates. NA = not active. 
 
  
Compound n R1 R2 EC50 (µM) CC50 (µM) SI  
(RS)-fluoxetine 2 4-CF3 
 
3.03 ± 0.56 18.81 ± 1.36 6.21  
(S)-fluoxetine 2 4-CF3 
 
0.50 ± 0.14 21.63 ± 1.40 43.26  
(R)-fluoxetine 2 4-CF3 
 
NA 18.82 ± 1.34 -  
1a  2 2-CF3 
 
NA >30 -  
1b 2 3-CF3 
 
NA 12.56 ± 1.79 -  
1c 2 2-Cl, 4-CF3 
 
NA 3.14 ± 0.07 -  
1d 2 2-OMe, 4-CF3 
 
NA 18.41 ± 1.26 -  
2a 1 4-CF3 
 
1.22 ± 0.15 >30 >24.60  
2b 2 4-CF3 
 
0.41 ± 0.27 >30 >73.17  
3 2 4-CF3 
 
NA >30 -  
4a 1 4-CF3 
 
4.2 ± 0.927 >30 >7.14  
 
  
Table 2. Comparison of compound cytotoxicity and antiviral activity (CVB3) in different 
cell lines. 
Shown are EC50 and CC50 values in µM. Data represents mean values ± standard deviation 
calculated from two independent experiments. Each experiment was done in biological 
triplicates.  
SI= Selectivity Index (CC50/EC50). Selectivity index was calculated from the averaged EC50 
and CC50 values of the independent experiments. 
 
 HelaR19 HEK293T HAP1 
Compound EC50 (µM) CC50 (µM) SI EC50 (µM) CC50 (µM) SI EC50 (µM) CC50 (µM) SI 
(RS)- 
fluoxetine 
2.70 ± 0.54 29.03 ± 1.04 
11 
1.41 ± 0.89 25.87 ± 1.45 
18 




0.62 ± 0.01 27.67 ± 0.87 
45 
0.7 ± 0.65 24.65 ± 2.56 
35 
0.69 ± 0.04 24.00 ± 1.87 
35 
2a 2.43 ± 0.32 56.78 ± 0.03 23 2.30 ± 0.44 45.87 ± 0.45 20 2.20 ± 0.32 40.72 ± 0.61 19 
2b 0.87 ± 0.98 64.99 ± 1.34 75 1.05 ± 0.02 52.98 ± 0.21 53 0.98 ± 0.21 49.39 ± 0.11 50 
 
  
Table 3. Broad-Spectrum antiviral activity of most potent compounds. 
Shown are EC50 values in µM. Data represents mean values ± standard deviation calculated 
from three independent experiments. Each experiment was done in biological triplicates  




Virus EV-A71 CVB3 PV-1 CV-A24 EV-D68 HRV-A2 HRV-B14 
Species EV-A EV-B EV-C EV-C EV-D RV-A RV-B 
Strain BrCr Nancy Sabin1 Joseph Fermon   
(RS)-fluoxetine NA 2.84 ± 0.73 NA NA 2.49 ± 0.23 NA NA 
(S)-fluoxetine NA 0.70± 0.14 NA NA 0.63 ± 0.17 6.99 ± 0.84 7.25 ± 0.69 
2a NA 1.98 ± 0.68 NA NA 3.03 ± 0.48 NA NA 
2b NA 0.87 ± 0.33 NA NA 0.56 ± 0.21 NA 3.33 ± 1.05 
Table 4. Antiviral activity of the 2b enantiomers. 
Shown are EC50 and CC50 values in µM. Data represents mean values ± standard deviation 




*subtle antiviral activity observed 
  
Compound EV-A71 CVB3 PV-1 CV-A24 EV-D68 HR-V2 HR-V14 CC50 
(S)-
fluoxetine 
>30 0.83 ± 0.29 >30 >30 0.68 ± 0.95 2.49 ± 2.5 3.76 ± 1.45 27.81 ± 0.95 
2b >30 0.81 ± 0.46 >30 >30 0.56 ± 0.77 >30 4.3 ± 2,98 60.76 ± 0.45 
(R)-2b >30 >30* >30 >30 4.13 ± 1.4 >30 >30 57.95 ± 0.65 
(S)-2b >30 0.19 ± 0.45 >30 >30 0.11 ± 0.02 7.49 ± 1.12 0.98 ± 1.25 59.6 ± 1.45 
Figure Legends 
 
Figure 1. Antiviral effect of analogue 2a and 2b on a panel of enteroviruses. 
In a single cycle assay Hela R19 cells were infected with different enterovirus species (A) EV-
A71 (strain BrCr) (B) CVB3 (strain Nancy) (C) poliovirus (strain Sabin). (D) CV-A24 (Strain 
Joseph) (E) EV-D68 (strain Fermon) (F) HRV-A2 (G) HRV-B14 at MOI 1 and treated with serial 
dilutions of (S)-fluoxetine (SFX) and the analogues 2a and 2b. As a control, guanidine 
hydrochloride (GuaHCl) was used as a pan-enterovirus inhibitor targeting 2C. At 8 or 10 hours 
post infection (depending on the virus, see Supplementary Information), cells were freeze-
thawed three times and virus titers of lysates were determined by endpoint titration. (H) In 
parallel, uninfected cells were treated with compound and cell viability was determined using 
an MTS assay. Data represent mean values  standard deviation from one representative of 
two independent experiments. Every experiment was performed in biological triplicates. 
 
 
Figure 2. Mutations in the CVB3-2C protein confer resistance to compound 2a and 2b. 
Hela R19 cells were infected with a selection of CVB3 viruses harbouring previously identified 
mutations in the non-structural protein 2C, which confer resistance towards (S)-fluoxetine 
(SFX). (20) Hela R19 were infected with and MOI 1 of (A) CVB3 wildtype virus. (B) the AVIVAV 
mutant (A224V-I227V-A229V triple mutant) (C) the I227V single mutant (D) the C179F and 
(E) the F190L mutant. Eight hours post infection cells were freeze-thawed three times and 
virus titers were determined with endpoint titration. Data represented show mean values  
standard deviation from one experiment representative of two independent experiments. 
Every experiment was performed in biological triplicates. 
 
 
Figure 3. The S-enantiomer of 2b exerts potent antiviral activity concomitant with 2C 
binding. (A) A Multicycle CPE reduction assay to determine the antiviral activity of the 
2b-enantiomers was performed. HeLa R19 cells were treated with serial dilutions of racemate, 
(S)-, or (R)- enantiomer of 2b and infected with CVB3 (strain Nancy), EVD68 (strain Fermon), 
HRV-2 (G) and HRV-14 at low MOI (depending on the virus, see Supplementary Information) 
to reach full CPE within three days. As positive control, cells were treated with (S)-fluoxetine. 
* indicates cytotoxicity of (S)-fluoxetine. Data shown are from one experiment representative 
of three independent experiments done in biological triplicates (B) The binding of the 
2b-enantiomers to a recombinant fragment of CVB3-2C was determined by thermal shift 
assay. The thermal stabilization of 2C is represented by change in melting temperature. The 
dashed line represents data from the negative control BF738735, a phosphateidylinositol-4-
kinase III beta inhibitor, used at a concentration of 250µM. Data shown is representative of 
two independent experiments, each of which was done in technical triplicates. Error bars 
depict standard deviation calculated from both experiments.   
 
